New guidelines on managing ovarian cancer in adolescents and young adults


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The European Society of Gynaecological Oncology (ESGO) and the European Society for Paediatric Oncology (SIOPE) have jointly developed evidence-based guidelines for the management of adolescents and young adults (AYA) aged 15 to 25 years with non-epithelial ovarian cancers, including malignant ovarian germ cell tumours, sex cord-stromal tumours, and small cell carcinoma of the ovary of hypercalcaemic type.

Given the specific and often complex issues involved in treating this group of patients, fertility sparing surgery and decrease of acute and long-term treatment-related toxicities are crucial.

These guidelines, published in Lancet Oncology, include recommendations on pre-operative diagnostic work-up for malignant ovarian germ cell tumours; the management of early-stage, advanced and refractory or recurrent disease; and follow-up and surveillance.

The management of sex cord-stromal tumours and small cell carcinoma of the ovary of hypercalcaemic type are dealt with separately in the guidelines, with recommendations on diagnosis, pathology, staging, and work-up, along with guidance on the management of early, advanced and recurrent or relapsed disease, including follow-up and surveillance.

The guidelines have been developed by an international multidisciplinary developmental group consisting of experts in paediatric oncology, paediatric surgery, medical oncology, pathology, psycho-oncology, gynaecological oncology, and reproductive endocrinology. Prior to publication, the guidelines were reviewed by 54 independent international practitioners in cancer care delivery.